The only Pharmaceutical Company from India to be recognized for IP-led Value Creation
Bengaluru, December 14, 2016: Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, has been recognized for its world class Intellectual Property (IP) management and IP value creation in the Asia region by IP Business Congress Asia (IPBC Asia) and has made its debut on the prestigious Asia IP Elite 2016 list. Biocon is the only pharmaceutical company out of the six Indian companies included in this exclusive group.
The prestigious list comprises 62 most influential companies from nine countries in Asia, such as Alibaba, Baidu, Canon, Fujifilm, Samsung Electronics, LG Electronics, Acer and ASUStek, which have all been recognized for excellence in IP and best in-class in-house IP functions.
The companies selected as the Asia IP Elite were honoured at the latest edition of the IP Business Congress Asia, held in Shanghai, which is the most important event addressing IP value creation to be held in Asia. The Congress was attended by over 400 senior IP decision makers from major IP owning companies.
Biocon has over the years built its credibility as an innovation-led enterprise through an excellent track record of intellectual property value creation in discovery, research and development. The Company has an IP portfolio of 1250 patent applications out of which 990 are granted patents and 820 trademark applications consisting of 460 registered trademarks.
Biocon Chairperson & Managing Director Kiran Mazumdar-Shaw said: “We are pleased to be the only pharma company from India to be recognized for our excellence in IP and included in the prestigious Asia IP Elite list 2016. In our pursuit of innovation, we have consistently created intellectual wealth through our incisive IP strategy which has not only given us a competitive advantage but also created exponential and enduring value for Biocon’s stakeholders.”
IPBC Asia is an event that addresses IP value creation and is hosted by Intellectual Asset Management, the publishers of the world’s leading IP magazine IAM. The IPBC Asia program is focused on how rights owners can strategically use intellectual property to secure greater operational flexibility, drive revenues, enhance bottom-line returns, increase shareholder value and gain greater leverage in the financial markets.
Through an extensive research process incorporating both quantitative and qualitative angles the IAM editorial team has identified 62 organisations across Asia to be inducted into the 2016 Asia IP Elite List.
Each Asia IP Elite member demonstrates excellence in IP value creation and adheres to the following criteria:
· Placing IP strategy at the centre of its business.
· Obtaining demonstrable, significant and on-going value from IP as a direct result of the strategies it employs.
· Ensuring that there is a direct line from its IP function to the senior management of the overall business.
· Possessing a senior management that understands the operational and strategic importance of IP.
· Constantly reappraising and improving its IP strategy in order to take advantage of market developments.
The 2016 Asia IP Elite: India | |
1 | Biocon |
2 | Wipro |
3 | Reliance Industries |
4 | Infosys |
5 | Tata Consultancy Services |
6 | Tata Technologies |
Corporate Comm India(CCI Newswire)